Benguet Corporation (PSE:BCB)

Market Cap	3.18B
Revenue (ttm)	2.90B
Net Income (ttm)	636.25M
Shares Out	n/a
EPS (ttm)	0.86
PE Ratio	4.99
Forward PE	n/a
Dividend	0.20 (4.30%)
Ex-Dividend Date	Nov 13, 2024

Volume	40,000
Average Volume	57,650
Open	4.650
Previous Close	4.440
Day's Range	4.650 - 4.650
52-Week Range	3.090 - 4.790
Beta	n/a
RSI	62.41
Earnings Date	Aug 15, 2025

About Revance Therapeutics

Benguet Corporation, together with its subsidiaries, engages in the research, development, exploration, and production of gold, nickel, and other metallic and nonmetallic mineral, and natural resource projects in the Philippines. It operates in four segments: Mining, Health Services, Logistics, and Others. It also holds interests in the Ampucao Copper-Gold, Pantingan Copper-Gold, Zamboanga Gold, Surigao Coal, Ilocos Norte, and Apayao FTAA prospects in the Philippines. In addition, the company provides medical and clinical diagnostic examination...

• Industry: Metals & Mining
• Sector: Materials
• Founded: 1903
• Employees: 1,244
• Stock Exchange: Philippine Stock Exchange
• Ticker Symbol: BCB

Financial Performance

In 2024, Benguet's revenue was 2.35 billion, a decrease of -6.05% compared to the previous year's 2.51 billion. Earnings were 435.61 million, a decrease of -21.38%.